Are you interested in medical weight loss but don't like needles? Micro Sema Capsules might be the perfect solution for you. [1]
Micro Sema is an oral form of semaglutide — the same active ingredient used in popular weight loss injections. Instead of weekly shots, you simply take a capsule daily. [2]
Key Benefits
- Completely needle-free
- Easy and convenient to take
- Same active ingredient as semaglutide injections
- Great option for people with needle phobia
- Can be taken from the comfort of your home
Who is it for?
Micro Sema Capsules are ideal for patients who want the benefits of semaglutide but prefer not to do injections. It's also a good option for those who want to start with a lower dose. [3]
Ready to explore a needle-free approach to weight loss?
Micro Sema Capsules are available in Florida for $109/mo, prescribed online by Florida-licensed clinicians. Visit our Micro Sema Capsules page to learn more and get started. [1]
Available across Florida
Reset My Vitality is a Florida-licensed telehealth practice. The treatments covered in this guide are available to patients statewide, with medication shipped directly to your door. Explore the program for your city:
- Weight Loss in Miami, FL
- Weight Loss in Miami Beach, FL
- Weight Loss in Fort Lauderdale, FL
- Weight Loss in West Palm Beach, FL
- Weight Loss in Boca Raton, FL
- Weight Loss in Orlando, FL
- Weight Loss in Tampa, FL
- Weight Loss in Jacksonville, FL
- Weight Loss in Naples, FL
Key Clinical Studies
A short, responsible summary of recent peer-reviewed research relevant to this topic. This is for education only, not medical advice.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine · 2021
Key finding: In a randomized controlled trial, participants on semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight at 68 weeks vs 2.4% on placebo, with 86% achieving at least 5% loss.
Why it matters: Establishes the efficacy of semaglutide for substantial, sustained weight loss when paired with lifestyle support.
View studyTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 2022
Key finding: Participants on tirzepatide 15 mg lost up to 20.9% of body weight at 72 weeks vs 3.1% on placebo, with 91% achieving at least 5% loss.
Why it matters: Shows the strong average results possible with the dual GLP-1/GIP agonist tirzepatide for eligible patients.
View studyTwo-year effects of semaglutide in adults with overweight or obesity (STEP 5)
Nature Medicine · 2022
Key finding: A 104-week trial found mean weight loss of 15.2% with semaglutide vs 2.6% with placebo, with weight loss largely maintained over two years on treatment.
Why it matters: Demonstrates long-term durability of GLP-1 weight loss when therapy is continued under clinical supervision.
View studyScientific References
Peer-reviewed studies and reviews cited in this article.
- [1]Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. View study
- [2]Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. View study
- [3]Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. View study
